A Study of LY3841136 in Overweight and Obese Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Obesity, Overweight
In brief
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
Key facts
- Study ID
- NCT06345066
- Run by
- Eli Lilly and Company
- People needed
- 96
- Starts
- 2024-04-03
- Expected to finish
- 2025-09-29
- Last updated by the study team
- 2025-10-15
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male and female participants who are overtly healthy as determined by medical evaluation
- Have a stable body weight and Body Mass Index in range of 27 to 45 kilogram per meter square (kg/m²).
- Have clinical laboratory test results within normal reference range
- Have venous access sufficient to allow for blood sampling
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
You may not qualify if…
- Have type 1 or type 2 diabetes mellitus
- Have an abnormal 12-lead electrocardiogram (ECG)
- Have a history or presence of psychiatric disorders
- Have abnormal blood pressure and pulse rate
- Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product.
Where it is running
- Fortrea Clinical Research Unit — Daytona Beach, Florida, United States
- Fortrea Clinical Research Unit — Dallas, Texas, United States
- Fortrea Clinical Research Unit — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.